Dong-A ST and Meiji Seika sign ustekinumab deal with Intas
Dong-A ST and Tokyo’s Meiji Seika Pharma have signed a deal with Ahmedabad, India’s Intas Pharmaceuticals to license DMB-3115, biosimilar referencing psoriasis treatment Stelara, the Korean company announced Wednesday.